DGIdb - CEDIRANIB Drug Record

CEDIRANIB chembl:CHEMBL491473 Antineoplastic

Alternate Names:

AZD-2171
CEDIRANIB
ZD-2171
RECENTIN
ZD 2171
AZD 2171
4-(4-FLUORO-2-METHYLINDOL-5-YLOXY)-6-METHOXY-7-[3-(PYRROLIDIN-1-YL)PROPOXY]QUINAZOLINE
chembl:CHEMBL491473
pubchem.compound:9933475
drugbank:04849
chemidplus:288383-20-0

Drug Info:

Pharmaceutical Developer	AstraZeneca
Source Reported Drug Name(s)	Cediranib maleate/ AZD2171/Recentin
Drug Class	VEGFR Inhibitor
Drug Class	Kinase Inhibitors
FDA Approval	not approved
Drug Class	Small molecule
Drug Indications	antineoplastic agent

(7 More Sources)

Publications:

Powles et al., 2016, A randomized, double-blind phase II study evaluating cediranib versus cediranib and saracatinib in patients with relapsed metastatic clear-cell renal cancer (COSAK)., Ann. Oncol.
Wedge et al., 2005, AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer., Cancer Res.
Liu et al., 2014, Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study., Lancet Oncol.
Friedman et al., 2015, Landscape of Targeted Anti-Cancer Drug Synergies in Melanoma Identifies a Novel BRAF-VEGFR/PDGFR Combination Treatment., PLoS ONE
Gozgit et al., 2012, Ponatinib (AP24534), a multitargeted pan-FGFR inhibitor with activity in multiple FGFR-amplified or mutated cancer models., Mol. Cancer Ther.
Nakanishi et al., 2015, Mechanism of Oncogenic Signal Activation by the Novel Fusion Kinase FGFR3-BAIAP2L1., Mol. Cancer Ther.

CEDIRANIB VHL

Interaction Score: 0.18

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy Cediranib + Saracatinib

Indication/Tumor Type renal clear cell carcinoma

Response Type no benefit

PMIDs:
26802156

Sources:
JAX-CKB
CEDIRANIB PTK6

Interaction Score: 0.17

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
CEDIRANIB BRCA2

Interaction Score: 0.11

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
25218906

Sources:
CIViC
CEDIRANIB FLT1

Interaction Score: 0.1

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Notes

Trial Name cediranib, AZD2171,Recentin

Novel drug target Established target

PMIDs:
None found

Sources:
TALC DTC TdgClinicalTrial ClearityFoundationClinicalTrial ChemblInteractions CancerCommons
CEDIRANIB FER

Interaction Score: 0.1

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
CEDIRANIB FGFR3

Interaction Score: 0.09

Interaction Types & Directionality:

n/a

Interaction Info:

Response Type resistant

Approval Status Preclinical - Cell culture

Response Type sensitive

PMIDs:
25589496 22238366

Sources:
DTC JAX-CKB
CEDIRANIB FLT4

Interaction Score: 0.08

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Novel drug target Established target

Trial Name cediranib, AZD2171,Recentin

Notes

PMIDs:
None found

Sources:
TALC DTC TdgClinicalTrial ClearityFoundationClinicalTrial ChemblInteractions
CEDIRANIB KDR

Interaction Score: 0.07

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Notes

Novel drug target Established target

Trial Name cediranib, AZD2171,Recentin

PMIDs:
15899831

Sources:
TALC MyCancerGenome TdgClinicalTrial ClearityFoundationClinicalTrial ChemblInteractions TTD
CEDIRANIB SRC

Interaction Score: 0.07

Interaction Types & Directionality:

n/a

Interaction Info:

Response Type no benefit

combination therapy Cediranib + Saracatinib

Indication/Tumor Type renal clear cell carcinoma

PMIDs:
26802156

Sources:
DTC JAX-CKB
CEDIRANIB ACVR1

Interaction Score: 0.07

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
CEDIRANIB CAMK2B

Interaction Score: 0.07

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
CEDIRANIB CHEK2

Interaction Score: 0.06

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
CEDIRANIB LTK

Interaction Score: 0.06

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
CEDIRANIB PDGFRB

Interaction Score: 0.06

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Notes

Mechanism of Interaction Platelet-derived growth factor receptor inhibitor

Direct Interaction yes

PMIDs:
None found

Sources:
TALC DTC ChemblInteractions
CEDIRANIB MST1R

Interaction Score: 0.06

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
CEDIRANIB STK3

Interaction Score: 0.05

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
CEDIRANIB AXL

Interaction Score: 0.05

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
CEDIRANIB FGFR2

Interaction Score: 0.05

Interaction Types & Directionality:

n/a

Interaction Info:

Response Type decreased response

Indication/Tumor Type Advanced Solid Tumor

Indication/Tumor Type endometrial cancer

PMIDs:
22238366

Sources:
JAX-CKB
CEDIRANIB MAP4K2

Interaction Score: 0.05

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
CEDIRANIB PLK4

Interaction Score: 0.05

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
CEDIRANIB MINK1

Interaction Score: 0.05

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
CEDIRANIB SYK

Interaction Score: 0.05

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
CEDIRANIB FRK

Interaction Score: 0.05

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
CEDIRANIB FGFR1

Interaction Score: 0.05

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type Advanced Solid Tumor

Response Type decreased response

Approval Status Preclinical

PMIDs:
22238366

Sources:
DTC JAX-CKB
CEDIRANIB SLK

Interaction Score: 0.04

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
CEDIRANIB KIT

Interaction Score: 0.04

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Notes

Mechanism of Interaction Stem cell growth factor receptor inhibitor

Direct Interaction yes

PMIDs:
None found

Sources:
TALC ChemblInteractions
CEDIRANIB TAOK1

Interaction Score: 0.04

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
CEDIRANIB PDGFRA

Interaction Score: 0.04

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Direct Interaction yes

Mechanism of Interaction Platelet-derived growth factor receptor inhibitor

PMIDs:
None found

Sources:
DTC ChemblInteractions
CEDIRANIB MAP4K5

Interaction Score: 0.04

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
CEDIRANIB ERBB4

Interaction Score: 0.04

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
CEDIRANIB BLK

Interaction Score: 0.04

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
CEDIRANIB PRKD2

Interaction Score: 0.04

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
CEDIRANIB FYN

Interaction Score: 0.04

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
CEDIRANIB MAP4K4

Interaction Score: 0.04

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
CEDIRANIB LYN

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
CEDIRANIB MAP2K2

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
CEDIRANIB CSF1R

Interaction Score: 0.03

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

PMIDs:
None found

Sources:
DTC
CEDIRANIB BRCA1

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
25218906

Sources:
CIViC
CEDIRANIB BRAF

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

Response Type sensitive

combination therapy Cediranib + Selumetinib + PLX4720

Indication/Tumor Type melanoma

PMIDs:
26461489

Sources:
JAX-CKB
CEDIRANIB LCK

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
CEDIRANIB ALK

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
CEDIRANIB AURKB

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
CEDIRANIB RET

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
CEDIRANIB ABL1

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
CEDIRANIB ERBB2

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
CEDIRANIB YES1

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC

MyCancerGenome: CEDIRANIB
- Version: 20-Jun-2017
Alternate Names:

CEDIRANIB Generic Name

RECENTIN Trade Name

Drug Info:

Drug Class Kinase Inhibitors

Publications:
CancerCommons: RECENTIN
- Version: 25-July-2013
Alternate Names:

Cediranib maleate PubChem Drug Name

11226834 PubChem Drug ID

Cediranib Drug Trade Name

Drug Info:

Drug Class VEGFR Inhibitor

Source Reported Drug Name(s) Cediranib maleate/ AZD2171/Recentin

Pharmaceutical Developer AstraZeneca

Publications:
TdgClinicalTrial: CEDIRANIB
- Version: January-2014
Alternate Names:

Drug Info:

Drug Indications antineoplastic agent

Drug Class Small molecule

FDA Approval not approved

Publications:

JAX-CKB: Cediranib

Version: 27-September-2017

Alternate Names:

Drug Info:

Publications:

Friedman et al., 2015, Landscape of Targeted Anti-Cancer Drug Synergies in Melanoma Identifies a Novel BRAF-VEGFR/PDGFR Combination Treatment., PLoS ONE

Gozgit et al., 2012, Ponatinib (AP24534), a multitargeted pan-FGFR inhibitor with activity in multiple FGFR-amplified or mutated cancer models., Mol. Cancer Ther.

Nakanishi et al., 2015, Mechanism of Oncogenic Signal Activation by the Novel Fusion Kinase FGFR3-BAIAP2L1., Mol. Cancer Ther.

CIViC: CEDIRANIB
- Version: 14-September-2020
Alternate Names:

Drug Info:

Publications:

Liu et al., 2014, Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study., Lancet Oncol.
TALC: CEDIRANIB
- Version: 12-May-2016
Alternate Names:

CEDIRANIB Primary Drug Name

CEDIRANIB Drug Generic Name

RECENTIN Drug Trade Name

Drug Info:

Publications:
DTC: CEDIRANIB
- Version: 02-September-2020
Alternate Names:

CHEMBL491473 ChEMBL Drug ID

Drug Info:

Publications:
TTD: Cediranib
- Version: 2020.06.01
Alternate Names:

D09VMI TTD Drug ID

Drug Info:

Publications:
ChemblInteractions: CHEMBL491473
- Version: chembl_23
Alternate Names:

Drug Info:

Publications:
ChemblDrugs: chembl:CHEMBL491473
- Version: ChEMBL_27
Alternate Names:

Drug Info:

Publications:
ClearityFoundationClinicalTrial: CEDIRANIB
- Version: 15-June-2013
Alternate Names:

Drug Info:

Publications:

combination therapy	Cediranib + Saracatinib
Indication/Tumor Type	renal clear cell carcinoma
Response Type	no benefit

Notes
Trial Name	cediranib, AZD2171,Recentin
Novel drug target	Established target

Response Type	resistant
Approval Status	Preclinical - Cell culture
Response Type	sensitive

Notes
Mechanism of Interaction	Platelet-derived growth factor receptor inhibitor
Direct Interaction	yes

Response Type	decreased response
Indication/Tumor Type	Advanced Solid Tumor
Indication/Tumor Type	endometrial cancer

Notes
Mechanism of Interaction	Stem cell growth factor receptor inhibitor
Direct Interaction	yes

Cediranib maleate	PubChem Drug Name
11226834	PubChem Drug ID
Cediranib	Drug Trade Name

CEDIRANIB	Primary Drug Name
CEDIRANIB	Drug Generic Name
RECENTIN	Drug Trade Name

CEDIRANIB Drug Record

CEDIRANIB chembl:CHEMBL491473 Antineoplastic

Alternate Names:

Drug Info:

Publications:

Interaction Types & Directionality: n/a

Interaction Info: combination therapy Cediranib + Saracatinib Indication/Tumor Type renal clear cell carcinoma Response Type no benefit

PMIDs: 26802156

Sources: JAX-CKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: DTC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 25218906

Sources: CIViC

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Notes Trial Name cediranib, AZD2171,Recentin Novel drug target Established target

PMIDs: None found

Sources: TALC DTC TdgClinicalTrial ClearityFoundationClinicalTrial ChemblInteractions CancerCommons

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: DTC

Interaction Types & Directionality: n/a

Interaction Info: Response Type resistant Approval Status Preclinical - Cell culture Response Type sensitive

PMIDs: 25589496 22238366

Sources: DTC JAX-CKB

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Novel drug target Established target Trial Name cediranib, AZD2171,Recentin Notes

PMIDs: None found

Sources: TALC DTC TdgClinicalTrial ClearityFoundationClinicalTrial ChemblInteractions

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Notes Novel drug target Established target Trial Name cediranib, AZD2171,Recentin

PMIDs: 15899831

Sources: TALC MyCancerGenome TdgClinicalTrial ClearityFoundationClinicalTrial ChemblInteractions TTD

Interaction Types & Directionality: n/a

Interaction Info: Response Type no benefit combination therapy Cediranib + Saracatinib Indication/Tumor Type renal clear cell carcinoma

PMIDs: 26802156

Sources: DTC JAX-CKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: DTC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: DTC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: DTC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: DTC

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Notes Mechanism of Interaction Platelet-derived growth factor receptor inhibitor Direct Interaction yes

PMIDs: None found

Sources: TALC DTC ChemblInteractions

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: DTC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: DTC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: DTC

Interaction Types & Directionality: n/a

Interaction Info: Response Type decreased response Indication/Tumor Type Advanced Solid Tumor Indication/Tumor Type endometrial cancer

PMIDs: 22238366

Sources: JAX-CKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy Cediranib + Saracatinib

Indication/Tumor Type renal clear cell carcinoma

Response Type no benefit

PMIDs:
26802156

Sources:
JAX-CKB

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
25218906

Sources:
CIViC

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Notes

Trial Name cediranib, AZD2171,Recentin

Novel drug target Established target

PMIDs:
None found

Sources:
TALC DTC TdgClinicalTrial ClearityFoundationClinicalTrial ChemblInteractions CancerCommons

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
DTC

Interaction Types & Directionality:

n/a

Interaction Info:

Response Type resistant

Approval Status Preclinical - Cell culture

Response Type sensitive

PMIDs:
25589496 22238366

Sources:
DTC JAX-CKB

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Novel drug target Established target

Trial Name cediranib, AZD2171,Recentin

Notes

PMIDs:
None found

Sources:
TALC DTC TdgClinicalTrial ClearityFoundationClinicalTrial ChemblInteractions

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Notes

Novel drug target Established target

Trial Name cediranib, AZD2171,Recentin

PMIDs:
15899831

Sources:
TALC MyCancerGenome TdgClinicalTrial ClearityFoundationClinicalTrial ChemblInteractions TTD

Interaction Types & Directionality:

n/a

Interaction Info:

Response Type no benefit

combination therapy Cediranib + Saracatinib

Indication/Tumor Type renal clear cell carcinoma

PMIDs:
26802156

Sources:
DTC JAX-CKB

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
DTC

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Notes

Mechanism of Interaction Platelet-derived growth factor receptor inhibitor

Direct Interaction yes

PMIDs:
None found

Sources:
TALC DTC ChemblInteractions

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
DTC

Interaction Types & Directionality:

n/a

Interaction Info:

Response Type decreased response

Indication/Tumor Type Advanced Solid Tumor

Indication/Tumor Type endometrial cancer

PMIDs:
22238366

Sources:
JAX-CKB

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
DTC

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type Advanced Solid Tumor

Response Type decreased response

Approval Status Preclinical

PMIDs:
22238366